

MATERIALS LICENSE  
SUPPLEMENTARY SHEET

License number 34-00398-08  
Docket or Reference number 030-02646

Amendment No. 25

St. Luke's Hospital  
11311 Shaker Blvd.  
Cleveland, OH 44104

In accordance with letter dated August 8, 1985, License Number 34-00398-08 is amended as follows:

Items 6., 7., 8. and 9. are amended to add:

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
H. Iodine-125	H. Any	H. 3 millicuries
I. Xenon-133	I. Gas or gas in solution that is the subject of an active (i.e., not withdrawn or terminated) "New Drug Application" (NDA) approved by FDA or an active (i.e., not withdrawn, terminated or on "clinical hold") "Notice of Claimed Investigational Exemption for a New Drug" (IND) that has been accepted by FDA	I. 1200 millicuries

9. Authorized Use

- H. To be used in DNA or protein labeling experiments.
- I. Blood flow studies. Pulmonary function studies.

Conditions 12. and 16. are amended to read:

12. Licensed material listed in Item 6 above is authorized for use by, or under the supervision of, the following individual(s) for the materials and uses indicated:

M. Rollins, M.D.

Groups I, II, III, IV, V and VI  
In vitro studies  
Xenon-133

Bennett Levine, M.D.

Groups I, II, III, IV and V  
In vitro studies  
Xenon-133

8509110417 850903  
REG3 LIC30  
34-00398-08 PDR

11 COPY 2  
mu30

BS. 9/3/85

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License number

34-00398-08

Docket or Reference number

030-02646

Amendment No. 25

Virginia Lampert, M.D.

Groups I, II and III  
Iodine-131 as iodide for treatment  
of hyperthyroidism and cardiac  
dysfunction

In vitro studies  
Xenon-133

D. J. Rynbrandt

In vitro studies

Wayne Hogrefe, Ph.D.

Hydrogen-3 for in vitro DNA studies  
Iodine-125 for DNA substrate/protein  
labeling

Ronald Thompson, M.D.

Groups I, II and III  
Iodine-131 for treatment of  
hyperthyroidism, cardiac  
dysfunction and thyroid carcinoma  
Phosphorus-32 (colloidal) for  
treatment of malignant effusions  
In vitro studies  
Xenon-133

16. Except as specifically provided otherwise by this license, the licensee shall possess and use licensed material described in Items 6, 7, and 8 of this license in accordance with statements, representations, and procedures contained in applications dated November 13, 1983, November 21, 1984, February 13, 1985 and August 8, 1985; and letter dated February 21, 1984. The Nuclear Regulatory Commission's regulations shall govern the licensee's statements in applications or letters, unless the statements are more restrictive than the regulations.

For the U.S. Nuclear Regulatory Commission

Original Signed

By William J. Adam, Ph.D.

Materials Licensing Section, Region III

Date September 3, 1985

COPY